Concord Drugs Ltd (BSE: 538965) is a Hyderabad, Telangana-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹90 Cr, it ranks #3,363 by market cap among the 6,137 Indian listed companies on FinBizNet, and #16 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹68.00 (as of 25 Oct 2026), the share price is 26.5% below its 52-week high of ₹92.52 and 7.9% above its 52-week low of ₹63.00. The share price is up 4.7% over one year and down 2.8% over three months.
| Current Price | ₹68.00 |
|---|---|
| Market Cap | ₹90 Cr |
| BSE Code | 538965 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 71.9 |
| Return on Equity | 2.55% |
| Return on Assets | 2.81% |
| 52-Week Range | ₹63.00 – ₹92.52 |
| 1-Year Price Change | +4.7% |
| 3-Month Price Change | -2.8% |
| Beta (1Y) | 0.63 |
| Headquarters | Hyderabad, Telangana |
| Website | concorddrugs.in |
Concord Drugs Limited engages in the manufacture and sale of pharmaceutical formulations in India. It offers tissue bio-adhesive products; ready-to-fill pellets and multiple unit pellets system; other drugs in the form of tablets, capsules, small volume parenterals, dry powders, syrups and suspension, and dry syrups; and hand sanitizers. The company was incorporated in 1995 and is based in Hyderabad, India.
1. Manufacture of Pharmaceutical Formulations-This segment manufactures and sells finished pharmaceutical formulations. 2. Segment Adjustment-0 3. Trading-This segment engages in trading of packing material.
1. Pharmaceutical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,73,448 Cr | 71.2 | 16.98% | ₹4,979 Cr | +28.0% |
| Aether Industries Limited | ₹20,419 Cr | 92.1 | 9.81% | ₹327 Cr | +88.8% |
| Alivus Life Sciences Ltd | ₹16,073 Cr | 27.7 | 18.36% | ₹640 Cr | +33.8% |
| Aarti Pharmalabs Ltd | ₹7,922 Cr | 43.2 | 8.49% | ₹536 Cr | -4.1% |
| Solara Active Pharma Sciences Limited | ₹3,361 Cr | -382.6 | -0.63% | ₹417 Cr | +3.3% |
| Sai Parenteral's Limited | ₹2,153 Cr | 110.9 | 2.88% | ₹179 Cr | — |
| KRM Ayurveda Limited | ₹556 Cr | 25.9 | — | ₹32 Cr | — |
| Trident Lifeline Limited | ₹501 Cr | 24.8 | — | — | +39.4% |
| Concord Drugs Ltd | ₹90 Cr | 71.9 | 2.55% | — | +4.7% |
Listed by market capitalisation. Ratios are shown for context only.
Concord Drugs Ltd is trading at ₹68.00, with a market capitalisation of ₹90 Cr.
Concord Drugs Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Concord Drugs Ltd has a P/E of 71.9 and a return on equity of 2.55%.
Concord Drugs Ltd is listed on the BSE under the scrip code 538965.
Concord Drugs Ltd's share price is up 4.7% over one year and down 2.8% over three months. Its 52-week range is ₹63.00 to ₹92.52.
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.